The patient with Parkinson's disease

Quintessence International

Volumn 34, Issue 5, 2003, Pages 379-393

  Dirks, Sarah J ^a   Paunovich, Eleonore D ^b   Terezhalmy, Geza T ^a   Chiodo, Laura K ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORIDE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

BRADYKINESIA; BURNING MOUTH SYNDROME; CLINICAL FEATURE; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DENTAL CARE; DENTAL HEALTH; DENTAL SURGERY; DIAGNOSTIC PROCEDURE; DISEASE CONTROL; DRUG MECHANISM; DYSPHAGIA; HUMAN; INFORMED CONSENT; MAXILLOFACIAL SURGERY; MEDICAL ASSESSMENT; MOTOR DYSFUNCTION; MOUTH DISEASE; MOUTH HYGIENE; MUSCLE RIGIDITY; NEUROSURGERY; ORAL SURGERY; PARKINSON DISEASE; PERIODONTICS; PRACTICE GUIDELINE; PREVENTIVE DENTISTRY; PROPHYLAXIS; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; TREMOR; UNITED STATES; XEROSTOMIA; ANAMNESIS; ARTICLE; DENTURE; INTERPERSONAL COMMUNICATION; MIDDLE AGED; MOTOR ACTIVITY; PERIODONTAL DISEASE; PHYSICAL EXAMINATION; TOOTH PLAQUE;

BURNING MOUTH SYNDROME; COMMUNICATION; DEGLUTITION DISORDERS; DENTAL CARE FOR CHRONICALLY ILL; DENTAL PLAQUE; DENTURES; HUMANS; MEDICAL HISTORY TAKING; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PERIODONTAL DISEASES; PHYSICAL EXAMINATION; XEROSTOMIA;

EID: 0042207641     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Lilienfeld DE, Perl DP. Projected neurogenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 1993;12:219-228.
2. Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health-System Pharmacy 2000;157:953-962.
3. Parkinson J. An essay on the shaking palsy. London: Whittingham & Rowland, 1817:B1.
4. Forno LS. Pathology of Parkinson's disease. In: Marsden CD, Fahn S (eds). Movement Disorders. London: Butterworth, 1982:25-40.
5. Ballard PA, Tetrud JW, Langston JW. Permanent parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology 1985;35:949-956.
6. Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1985;312:1418-1421.
7. Singer TP, Castagnoli N Jr, Ramsay RR, Trevor AJ. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) J Neurochem 1987;49:1-8.
8. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3(12):1301-1306.
9. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42:1328-1335.
10. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: A case-control study in China. Neurology 1989;39:660-664.
11. Wong GF, Gray C, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson's disease. Arch Neurol 1991;48:287-289.
12. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry 1996;61:4-16.
13. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 2001;293(5528):263-269.
14. Haas C, Kahle PL. Parkin and its substrates. Science 2001;293:224-225
15. Tanner CM, Ottoman R, Goldan SM, et al. Parkinson disease in twins: An etiologic study. JAMA 1999;281:341-346.
16. Cummings JL. Understanding Parkinson Disease. JAMA 1999;281:376-377.
17. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;13:293:224-225.
18. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the gene encoding alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
19. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's Disease. Nat Genet 1998;18:106-108.
20. Goedert M. Familial Parkinson's Disease: The awakening of alpha-synuclein. Nature 1997;388:232-233.
21. Leroy E, Boyer R, Augerger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
22. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-265.
23. Farrer M, Gwinn-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 1999;8:81-85.
24. Lucking CB, Durr A, Bonifati V, Vaughan J, et al. Association between early-onset Parkinson's disease and mutations in the PARKIN gene. N Eng J Med 2000;342:1560-1567.
25. Schapira AH. Mitochondrial complex I deficiency in Parkinson's disease. Adv Neurol 1993;60:288-291.
26. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998;13(suppl 1):24-34.
27. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366.
28. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998;44(suppl 1):S110-S114.
29. Mattammal MB, Haring JH, Chung HD, Raghu G, Strong R. An endogenous dopaminergic neurotoxin: Implication for Parkinson's disease. Neurodegeneration 1995;4:271-281.
30. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 2000;60:552-558.
31. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373:339-341.
32. Burke RE, Kholodilov NG. Programmed cell death: Does it play a role in Parkinson's disease? Ann Neurol 1998;44 (suppl 1):S110-S114.
33. Lilienfeld DE, Chan E, Ehland J, et al. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol 1990;47:731-734.
34. Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson's disease. In: Watts RL, Coller WC (eds). Movement Disorders, Neurologic Principles and Practices. New York: McGraw-Hill, 1997:137-152.
35. Moghal S, Rajput AH, D'Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994;13:175-178.
36. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol 1997;54:260-264.
37. Fox C, Ramig L. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am J Speech-Language Pathol 1997;6:85-94.
38. Marder K, Leung D, Tand M, et al. Are demented patients with Parkinson's disease accurately reflected in prevalence surveys? A survival analysis. Neurology 1991;41:1240-1243.
39. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burdens of Parkinson's disease. Mov Disord 1998;13:406-413.
40. Koller WC. How accurately can Parkinson's disease be diagnosed? Neurology 1992;42(suppl 1):6-16.
41. Koller WC, Montgomery EB. Issues in the early diagnosis of Parkinson's disease. Neurology 1997;49(suppl 1):S10-S25.
42. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 2000;60:552-558.
43. Koller WC, Minagar A. Treatment strategies for the management of Parkinson's disease. In: PDR 2000-Parkinson's Disease Management Guide. Montvale, NJ: Medical Economics, 2000:101-130.
44. Fahn S, Elton R, and the members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. Available at www.wemove.org/parrate.html Accessed: January 8, 2003.
45. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-442.
46. Hoehn scale and Yahr scale. Available at: wwwgeocities.com/pdcaregiver/stages of parkinsons.html Accessed:
47. Obeso JA, Rodriquez-Oroz MC, Rodriquez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease [review]. Trends Neurosci 2000;23(10 suppl):S8-S19.
48. Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 2000;23(10 suppl):S28-S33.
49. Jankovic J. Parkinson's disease therapy: Tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 2000;23(5):252-261.
50. Abramiwich M. Drugs of choice from the medical letter. The Medical Letter on Drugs and Therapeutics, ed 14. New Rochelle, NY: The Medical Letter, 2001:151-161.
51. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology 1998;50(suppl 3):51-55.
52. Lang AE. Surgery for Parkinson disease: A critical evaluation of the state of the art. Arch Neurol 2001;58(2):315-316.
53. Koller WC, Pahwa R, Lyons KE, Albanese A. Surgical treatment of Parkinson's disease [review]. J Neurol Sci 1999;167:1-10.
54. Krack P, Hamel W, Mehdorn HM, Deuschl G. Surgical treatment of Parkinson's disease. Curr Opin Neurol 1999;12:417-425.
55. Scully C, Cawson R. Medical Problems in Dentistry, ed 4. Butterowrth-Heine London: Wright, 1998:362-365.
56. Steifler M, Hofman S. Disorders of verbal expression in Parkinsonism. Adv Neurol 1984;40:385-393.
57. Diamond SG, Schneider JS, Markham CH. Oral sensimotor defects in patients with Parkinson's disease. Adv Neurol 1986;45:335-338.
58. Robbins JA, Logemann JA, Kitshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol 1986;19:283-287.
59. Clifford T, Finnerty J. The dental awareness and needs of a Parkinson's disease population. Gerodontology 1995;12:99-103.
60. Jolly DE, Paulson RB, Paulson GW, Pike JA. Parkinson's disease: A review and recommendations for dental management. Spec Care Dentist 1989;9:74-78.
61. Fiske J, Hyland K. Parkinson's disease and oral care. Dental Update 2000;27:58-65.
62. Clifford TJ, Warsi MJ, Burnett CA, Lamey PJ. Burning mouth in Parkinson's disease sufferers. Gerodontology 1998;15:73-78.
63. Niessen LC, Jones JA. Professional dental care for patients with dementia. Gerodontology 1987;6:67-71.
64. The National Parkinson Foundation. Drugs contraindicated in Parkinson's disease. Available at www.parkinson.org/medD.htm Accessed January 7, 2003.
65. Park KK, Matis BA, Christen AG. Choosing an effective toothbrush. Clin Prev Dent 1985;7:5-9.
66. Youngblood JJ, Killoy W, Love JW, Drisko C. Effectiveness of a new home plaque-removal instrument in removing subgingival and interproximal plaque: A preliminary in vivo report. Compend Contin Educ Dent 1985;(suppl 6):S128-S132.
67. Baab DA, Johnson RH. The effect of new electric toothbrush on supragingival plaque and gingivitis. J Periodontol 1989;60:336-341.
68. Killoy WJ, Love JW, Love J, Fedi PF Jr, Tira DE. The effectiveness of a counter-rotary action powered toothbrush and conventional toothbrush on plaque removal and gingival bleeding. A short-term study. J Periodontol 1989;60:473-477.
69. Wilcoxon DB, Ackerman RJ Jr, Kolloy WS, Love JW, Sakumura JS, Tira DE. The effectiveness of a counter-rotational action power toothbrush on plaque control in orthodontic patients. Am J Orthod Dentofac Orthop 1991;99:7-14.
70. Wilson S, Levine D, Dequincy G, Killoy W. Effects of two toothbrushes on plaque, gingivitis, gingival abrasion and recession: A one-year longitudinal study [abstract 1840]. J Dent Res 1993;72:333.
71. Wilson S, Levine D, Dequincy G, Killoy WJ. Effects of two toothbrushes on plaque, gingivitis, gingival abrasion and recession: A one-year longitudinal study. Compend Contin Educ Dent 1993;14(suppl 16):S69-S79.
72. Yukna RA, Shaklee RL. Interproximal vs midradicular effects of a counterrational powered brush during supportive periodontal therapy. Compend Contin Educ Dent 1993;14(suppl 16):S80-S586.
73. Love JW, Drisko CL, Killoy WJ, Tira DE, Love JD. Clinical assessment of the INTERPLAKR powered toothbrush vs a conventional brush plus floss. Compend Contin Educ Dent 1993;14(suppl 16):S87-S98.
74. Blahunt P. A clinical trial of the INTERPLAKR powered toothbrush in a geriatric population. Compend Contin Dent 1993;14(suppl 16):S606-S610.
75. Terezhalmy GT, Gagliardi VB, Rybicki LA, Kauffman MJ. Clinical evaluation of the efficacy and safety of the UltraSonex ultrasonic toothbrush: A 30-day study. Compendium 1994;15:866,868,870-872.
76. Terezhalmy GT, Iffland H, Jelepis C, Waskowski J. Clinical evaluation of the effect of an ultrasonic toothbrush on plaque, gingivitis, and gingival bleeding: A six-month study. J Prosthet Dent 1995;73:97-103.
77. Whitmyer CC, Terezhalmy GT, Miller DL, Hujer ME. Clinical evaluation of the efficacy and safety of an ultrasonic toothbrush system in an elderly patient population. 1998;19:29-33.
78. Keltjens H, Schaeken T, van der Hoeven H. Preventive aspects of root caries. Int Dent J 1993;43:143-148.
79. Ten Cate JM, Parsh PD. Procedures for establishing efficacy of antimicrobial agents for chemotherapeutic caries prevention. J Dent Res 1994;73:695-703.
80. Robbins JA, Logemann JA, Kirschner HS. Swallowing and speech production in Parkinson's Disease. Ann Neurol 1986;19:283-287.